Ed Paiewonsky, Director, Medical Outcomes Science Liaison at Alnylam Pharmaceuticals, discussed results of the Alnylam Rare Disease Trend report at this year's Asembia Specialty Pharmacy Summit. Key rare disease trends included the increased focus in rare disease management, sites of care policies increasing, uncertainty around recent federal legislation and how these changes will affect payers and rare disease industry.

свернуть